Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT05208762 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT05208762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05208762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Recruiting
Start date
October 25, 2022
Completion date
January 4, 2029
Enrollment
714 (estimated)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, endometrial cancer, esophageal squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, pancreatic adenocarcinoma, squamous cell carcinoma of the head and neck, triple negative breast neoplasms